BIIB Stock Analysis
NMS · Healthcare · Drug Manufacturers - General
$226.56
-1.04 (-0.46%)
BIIB Interactive Price Chart & Trading Signals
BIIB Stock Snapshot — Valuation, Risk & Technical Signals
BIIB Key Fundamentals, Analyst Targets & Company Profile
Key Financial Ratios
Market Cap
$33.48B
P/E Ratio
40.31
Forward P/E
13.70
PEG Ratio
2.35
P/B Ratio
1.78
EPS
$5.62
Dividend Yield
—
52W Range
$135.39 – $229.19
Beta
0.17
Volume
0.0M
ROE
4.6%
Profit Margin
8.3%
Revenue Growth
3.4%
Gross Margin
78.3%
EV/EBITDA
12.12
Analyst Target
$238.18
The trailing price-to-earnings ratio stands at 40.3x. Forward P/E of 13.7x implies earnings expansion expected. Price-to-book is 1.78x. EV/EBITDA sits at 12.12x. Market capitalization is $33.48B. Revenue is growing at 3.4% on a trailing basis. Earnings are compressing at -84.8%. Profit margins are 8.3%. Return on equity is 4.6%. Beta of 0.17 indicates defensive profile.
Analyst Consensus
Recommendation
Buy
Low Target
$175.00
Mean Target
$238.18
High Target
$300.00
Based on 31 analysts
About BIIB
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
BIIB Deep Dive Analysis
Bottom Line
Verdict
OvervaluedBest for
General investorWatch out for
Premium valuation, Earnings declineNon-zero inputs
4/5Counts non-zero values for price, P/E, beta, macro risk, and revenue growth; zero may mean unavailable or be a genuine zero.
Biogen Inc. (BIIB) trades above our multi-model fair value estimate of $125.71 by approximately 44.5%. Trailing P/E: 40.3x. Profitability signals include profit margin of 8.3% and return on equity of 4.6%. Recent growth metrics show revenue growth of 3.4% and earnings growth of -84.8%. Risk profile: defensive beta of 0.17. Consensus: buy.
Valuation, Growth & Risk
Valuation
Overvalued
P/E 40.3x
Price is above what fundamentals suggest.
Growth
Stable
Rev 3.4%
Revenue is moving sideways.
Risk
Low
Beta 0.17
Movement is likely to track the broader market.
Valuation Snapshot
Biogen Inc. (BIIB) trades above our multi-model fair value estimate of $125.71 by approximately 44.5%. The trailing price-to-earnings ratio stands at 40.3x. Forward P/E of 13.7x suggests earnings compression ahead. Price-to-sales is 3.3x. Price-to-book is 1.8x. EV/EBITDA sits at 12.1x. Market capitalization is $33.48B.
Why it matters: Paying a premium works only if the company keeps growing faster than expected.
Growth & Profitability
Revenue is growing at 3.4% on a trailing basis. Earnings are compressing at -84.8%. Profit margins are 8.3%. Return on equity is 4.6%. Return on assets is 5.2%.
Why it matters: Stable revenue is fine, but watch for margin pressure that could limit profit growth.
Risk Profile
Beta of 0.17 indicates defensive profile. Net debt position is $7.07B.
Why it matters: Lower risk means steadier returns, but often with less upside in bull markets.
Analyst Context
Analyst consensus target of $238.18 implies 5.1% upside. Target range spans $175.00 to $300.00. 31 analysts cover the stock. Consensus recommendation: buy.
Why it matters: Analyst targets reflect what professionals expect over 12 months. A wide gap between price and target can mean the market disagrees with the consensus.
Investor Fit
Free cash flow yield of 5.9% is attractive for cash-flow-focused investors.
Takeaway: Match the stock's risk-reward profile with your own goals and time horizon. No single metric tells the whole story.
Data Methodology & Sources
Market Data (Facts)
- Price, volume, and market cap: Yahoo Finance (may be delayed)
- P/E, EPS, revenue, and debt: Yahoo Finance fundamentals
- Analyst estimates: Yahoo Finance (coverage and update times vary)
- Insider transactions: Yahoo Finance (reporting may be delayed)
QuantSoar Model (Derived)
- Fair value: available outputs from seven models; outliers are filtered using MAD (k=3.5), then combined with fixed model weights.
- Margin of Safety = (Fair Value − Displayed Price) / Displayed Price × 100
- Composite Score: 40% Value + 30% Momentum + 30% Risk
- Verdict Gauge: Base 50 + Valuation (up to ±25) + Whale sentiment (up to ±10) + Insider buying (+5) + Macro risk (up to ±10) + Technical signal (up to ±10). Analyst consensus is separate.
Model outputs are estimates based on available data and are not investment advice. Cross-check with primary sources before making investment decisions.
BIIB Overvalued
Biogen Inc. (BIIB) trades above our multi-model fair value estimate of $125.71 by approximately 44.5%.
Frequently Asked Questions
ValuationIs BIIB stock overvalued right now?
ValuationWhat is BIIB fair value based on current fundamentals?
RiskHow risky is BIIB compared with other stocks?
GrowthIs BIIB still growing?
AnalystWhat do analysts think about BIIB?
CatalystWhat could change the investment case for BIIB?
Related Stocks
About the Author
Phasakorn Traklang (Peach) — Founder
Phasakorn Traklang (Peach) is the founder of QuantSoar, bringing expertise in SEO, web development, and technical analytics to build an AI-powered investment platform accessible to retail investors worldwide.
Connect on LinkedInInvestment Disclaimer: Tax treatment can depend on tax residence, account type, and tax year. This information is general and is not personal tax or investment advice. SEC
Data: Yahoo Finance / SEC EDGAR / Alpha Vantage / Finnhub. AI outputs verified against source data.